Asset
LEXANERSEN SODIUM
Wave Life Sciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04617860 | phase1_2 | terminated | 2019-09-24 | 2021-04-29 | Wave Life Sciences USA, Inc. | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease |
| NCT03225846 | phase1_2 | terminated | 2017-07-17 | 2021-05-10 | Wave Life Sciences USA, Inc. | Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease |
FDA applications (0)
This company has no applications containing this asset.